Merck is in advanced talks to purchase Seagen in a $40 billion deal; data shows approximately 7215 confirmed monkeypox cases globally; FDA permits pharmacists to prescribe Pfizer’s COVID-19 antiviral pill, Paxlovid.
Merck & Co is in advanced talks to purchase Seagen Inc, The Wall Street Journal reported. According to sources close to the matter, the purchase could be worth at least $40 billion and is expected to be made in the coming weeks, though there is no guarantee the 2 companies will come to an agreement on a takeover deal. Merck and Seagen are currently discussing a price of more than $200 a share for the cancer biotechnology company, and plan to confirm the deal during or prior to the announcement of Merck’s quarterly earnings on July 28.
CIDRAP reported that the World Health Organization (WHO) announced there are now more than 6000 monkeypox cases across 58 countries with approximately 80% of cases in European countries. According to data from Our World in Data, there are 7215 confirmed cases as of July 6. Beginning yesterday, Labcorp has begun testing for monkeypox virus in the United State and claims it is able to process 10,000 tests weekly. The WHO Emergency Committee plans to meet again July 18 or sooner to reassess the outbreak and discusses what actions need to be taken to minimize spread.
Under a new FDA order, state-licensed pharmacists are allowed to prescribe Pfizer’s COVID-19 antiviral pill, Paxlovid, Bloomberg reported. The FDA said there are some limitations to ensure appropriate treatment for patients, and individuals who test positive for COVID-19 should still seek care from their primary care doctor or a test-to-treat site first. Individuals seeking a pharmacist’s prescription are advised to bring a complete list of medications being taken so the pharmacist can assess potential drug interactions, and a blood test result from within the last 12 months.
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines
September 6th 2025National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American College of Chest Physicians (CHEST) offer complementary yet distinct frameworks for lung cancer care, reflecting differences in evidence evaluation, regional adaptation, and policy integration.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen